Taipei Exchange - Delayed Quote TWD

Orient EuroPharma Co., Ltd. (4120.TWO)

48.90
+0.20
+(0.41%)
At close: 1:30:39 PM GMT+8
Loading Chart for 4120.TWO
  • Previous Close 48.70
  • Open 48.00
  • Bid 48.30 x --
  • Ask 48.90 x --
  • Day's Range 48.00 - 48.90
  • 52 Week Range 40.05 - 60.70
  • Volume 15,185
  • Avg. Volume 99,806
  • Market Cap (intraday) 4.242B
  • Beta (5Y Monthly) 0.19
  • PE Ratio (TTM) --
  • EPS (TTM) -4.00
  • Earnings Date --
  • Forward Dividend & Yield 1.00 (2.05%)
  • Ex-Dividend Date Jul 19, 2024
  • 1y Target Est --

Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.

www.oepgroup.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4120.TWO

View More

Performance Overview: 4120.TWO

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

4120.TWO
1.45%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.92%

1-Year Return

4120.TWO
18.95%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.55%

3-Year Return

4120.TWO
47.89%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
34.23%

5-Year Return

4120.TWO
7.78%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.45%

Compare To: 4120.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4120.TWO

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    4.22B

  • Enterprise Value

    6.70B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.95

  • Price/Book (mrq)

    0.77

  • Enterprise Value/Revenue

    1.51

  • Enterprise Value/EBITDA

    51.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -7.83%

  • Return on Assets (ttm)

    -0.51%

  • Return on Equity (ttm)

    -5.54%

  • Revenue (ttm)

    4.44B

  • Net Income Avi to Common (ttm)

    -347.8M

  • Diluted EPS (ttm)

    -4.00

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.68B

  • Total Debt/Equity (mrq)

    69.10%

  • Levered Free Cash Flow (ttm)

    42.78M

Research Analysis: 4120.TWO

View More

Company Insights: 4120.TWO

Research Reports: 4120.TWO

View More

People Also Watch